STEEN Solution™ approved in China

XVIVO Perfusion has received approval of STEEN Solution™ by the China Food and Drug Administration (CFDA). This enables the company to market and sell STEEN Solution™ for clinical use in China.

CFDA has approved STEEN Solution ™ for lung transplantation, which allows sales of STEEN Solution ™ for clinical use in lung transplants in China. China currently accounts for less than five percent of all lung transplants in the world, despite the large share of the world’s population, but the market has shown rapid growth in recent years and there is a great need for more donated lungs for lung transplantation.

"The approval of STEEN Solution ™ in China is important for future growth because there is a great need for lung transplants and an interest in utilizing EVLP with STEEN Solution ™ to increase the availability of usable donor lungs. To be present early in the growth phase and establish the products increases the chances of becoming a leader when the market matures," says Magnus Nilsson, CEO of XVIVO Perfusion.

November 20, 2015
Gothenburg
XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, 1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com

The information was submitted for publication on November 20, 2015 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.